Medpace

clinical research clinical development medpace clinical trials drug development rare diseases cro oncology clinical operations late phase covid-19 radiopharmaceuticals advanced therapies immuno-oncology biomarker laboratory precision medicine compliance pharmacoeconomic assessment quality assurance pediatric rare disease risk management outcomes research clinical trial clinical pharmacology medical device regulatory approval mike winegar biomarkers cardiovascular dosimetry gene therapies cell therapies chronic kidney disease radiation therapy acute myeloid leukemia pediatric cancer research cancer patient recruitment imaging neuroscience relationships regulatory affairs sponsor medical devices commercialized hematology risk-based monitoring regulatory asia pacific pharmaceutical market approval good clinical practice surveillance audits pharmacovigilance safety orphan drug post-authorization studies safety surveillance registries randomized clinical trials expanded access programs clinical studies safety efficacy studies randomised clinical trials observastion studies phase iv phase iiib observational studies patient registries asia xiaoxiong wei drug development china regulatory compliance china jim wei early phase cincinnati cpu phase i phase i/iia biosimilars china fda jimwei medpacema separate tags by comstrategic partnership debbie elliott strategic partnering outsourcing strategy alzheimers's medpace medical consulting dr. ursula schlichtiger regulatory compliance fim device trials safety device trials pivotal device trials medical device clinical trial medical device regulatory reform medical device medpace medical device